Table 2.

Main results of stratified analyses for the impact of HS-mGPS on overall survival.

Subgroup	No. of Datasets (Patients)	HR (95% CI)	p Value	Heterogeneity Test
				I2 %	p Value
Total	20 (5545)	2.17 (1.80–2.60)	<0.001	65.5	<0.01
Tumor site
Gastrointestinal cancer	11 (4073)	1.90 (1.53–2.35)	<0.001	70.14	<0.01
Gastric cancer	4 (1383)	1.79 (1.28–2.49)	=0.001	73.41	0.01
Esophageal cancer	2 (163)	2.50 (1.17–5.34)	0.018	79.64	0.03
Hepatocellular carcinoma	2 (1625)	1.39 (1.18–1.65)	<0.001	0	0.63
Gallbladder cancer	2 (144)	2.43 (1.30–4.55)	0.006	66.86	0.08
Colorectal cancer	1 (595)	2.64 (1.05–6.64)	0.039
Head and neck cancer	5 (653)	2.88 (2.07–4.01)	<0.001	0	0.62
Oropharyngeal cancer	1 (106)	5.78 (2.25–14.85)	<0.001
Hypopharyngeal cancer	1 (115)	2.68 (1.19–6.04)	0.017
Oral cancer	1 (303)	2.56 (1.53–4.30)	<0.001
Mixed	2 (129)	2.64(1.44–4.85)	0.002	0	0.64
Soft tissue sarcoma	2 (524)	2.19 (1.41–3.40)	<0.001	79.19	0.03
Lung cancer	1 (327)	2.78 (1.21–6.38)	0.016
Prostate cancer	1 (131)	2.41 (1.31–4.45)	0.005
Region
China	9 (2911)	1.92 (1.48–2.48)	<0.001	73.74	<0.01
Japan	10 (2331)	2.43 (1.88–3.15)	<0.001	37.21	0.11
Taiwan	1 (301)	2.56 (1.53–4.30)	<0.001
Sample size
<165	10 (858)	2.75 (2.12–3.56)	<0.001	36.15	0.12
≥165	10 (4687)	1.74 (1.44–2.10)	<0.001	55.08	0.02
Cutoff value of HS-mGPS
2	6 (2822)	2.82 (1.95–4.07)	<0.001	50.77	0.07
1	5 (2495)	1.51 (1.30–1.75)	<0.001	0	0.64
≥1	9 (2723)	2.20 (1.66–2.92)	<0.001	65.76	0.01
Analysis method
Multivariable	17 (4656)	2.24 (1.83–2.75)	<0.001	60.83	<0.01
Univariable	3 (889)	1.92(1.06–3.50)	=0.032	81.67	<0.01

Abbreviations: CI, confidence interval; HR, hazard ratio; HS-mGPS, high-sensitivity modified Glasgow Prognostic Score; No., number.